13.19
-1.31 (-9.03%)
| Penutupan Terdahulu | 14.50 |
| Buka | 13.17 |
| Jumlah Dagangan | 421,346 |
| Purata Dagangan (3B) | 195,838 |
| Modal Pasaran | 1,705,236,864 |
| Harga / Jualan (P/S) | 30.52 |
| Harga / Buku (P/B) | 2.97 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -633.21% |
| EPS Cair (TTM) | -1.24 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -6.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 27.34% |
| Nisbah Semasa (MRQ) | 0.960 |
| Aliran Tunai Operasi (OCF TTM) | -42.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.46 M |
| Pulangan Atas Aset (ROA TTM) | -4.85% |
| Pulangan Atas Ekuiti (ROE TTM) | -21.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Mesoblast Limited | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -4.0 |
| Purata | -0.75 |
|
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 0.06% |
| % Dimiliki oleh Institusi | 3.10% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Penbrook Management Llc | 31 Mar 2026 | 87,075 |
| Rialto Wealth Management, Llc | 31 Mar 2026 | 46,500 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |